A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

October 4, 2023

Study Completion Date

October 4, 2023

Conditions

Healthy

Interventions

DRUG

Nipocalimab

Nipocalimab will be administered as an IV infusion.

BIOLOGICAL

Tdap

Tdap will be administered as an IM injection.

BIOLOGICAL

PPSV23

PPSV23 will be administered as an IM injection.

Trial Locations (1)

CRS Clinical Research Services Berlin GmbH, Berlin

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY